Clinical Trial: Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Study Status: Completed
Recruit Status: RECRUITING
Condition: Age-Related Macular Degeneration
Study Type: INTERVENTIONAL
Official Title: A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Brief Summary:
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD.KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector.The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid.A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.
Read more